We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Privacy Terms and Cookie Policy
Balanced Reporting. Trusted Insights.
Thursday, April 03, 2025
The Justice Department has decided to approve Bayer’s acquisition of Monsanto after DOJ and the two companies reached an “agreement in principle,” according to the Wall Street Journal.
It was the battle of the experts at what was dubbed "Science Week" in a federal court in California last week, as lawyers for plaintiffs and for defendant Monsanto put witnesses on the stand who tried to explain the intricacies of toxicology and epidemiology to a federal and a state judge.
Bayer says it is pushing back the expected date of closing its proposed $66 billion acquisition of Monsanto Co. and that it is prepared to make additional concessions – including selling its entire vegetable seed business – to win approval from antitrust authorities in the EU, the U.S. and elsewhere.
The flurry of consolidations in the ag industry has presented a new topic for debate in many recently-rearranged boardrooms: What in the heck should we call this thing?
The Trump administration’s approach to mergers and acquisitions in the agriculture-related industries appears to follow the antitrust enforcement policies of previous administrations, in the view of a former Department of Justice (DOJ) antitrust lawyer.
California cannot force Monsanto and other companies to place warning labels on products containing glyphosate, a federal judge ruled Monday, delivering a major victory to Monsanto and a collection of agricultural groups.
Historically, farmers and ranchers have looked to USDA and their universities to develop the “next big thing” in plant and animal breeding, but exciting new players are emerging.
An Arkansas state court judge has thrown out Monsanto's lawsuit against the Arkansas State Plant Board that challenged an April 16-Oct. 31 ban on dicamba this growing season.
The International Agency for Research on Cancer received a fresh round of criticism Tuesday on Capitol Hill for its review of glyphosate, which IARC found to be a probable human carcinogen three years ago.
